CRISPR Therapeutics to Present at Upcoming Investor Conferences
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
View All Press
CRISPR Therapeutics Corporate Presentation
CRISPR Therapeutics Data Update Call Presentation
2019 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: Single-cell RNA sequencing and functional assessment of healthy donor- and cancer patient-derived T and CAR-T cells
2019 European Association for the Study of Diabetes (EASD) Presentation
View All Presentations
CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference